| 1 |
Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American Aociety of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34(21):2541-56.
doi: 10.1200/JCO.2016.67.5553
|
| 2 |
Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2017; 35(20):2324-8.
doi: 10.1200/JCO.2017.72.4948
|
| 3 |
Kanno A, Masamune A, Hanada K, Maguchi H, Shimizu Y, Ueki T, et al. Multicenter study of early pancreatic cancer in Japan. Pancreatology. 2018; 18(1):61-7.
doi: 10.1016/j.pan.2017.11.007
|
| 4 |
Javadi S, Karbasian N, Bhosale P, de Castro Faria S, Le O, Katz MH, et al. Imaging findings of recurrent pancreatic cancer following resection. Abdom Radiol (NY). 2018; 43(2):489-96.
doi: 10.1007/s00261-017-1397-8
pmid: 29198001
|
| 5 |
Sohal DPS, Mangu PB, Khorana AA, Shah MA, Philip PA, O’Reilly EM, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34(23):2784-96.
doi: 10.1200/JCO.2016.67.1412
|
| 6 |
Katz MH, Wang HM, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009; 16(4):836-47.
doi: 10.1245/s10434-008-0295-2
|
| 7 |
Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, et al. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013; 20(7):2197-203.
doi: 10.1245/s10434-013-2889-6
|
| 8 |
Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther. 2016; 9:7459-67.
doi: 10.2147/OTT
|
| 9 |
Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma. Abdom Radiol (NY). 2018; 43(2):505-13.
doi: 10.1007/s00261-017-1316-z
pmid: 28900703
|
| 10 |
Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol. 2013; 19(29):4808-17.
doi: 10.3748/wjg.v19.i29.4808
|
| 11 |
Rustagi T, Gleeson FC, Chari ST, Abu Dayyeh BK, Farnell MB, Iyer PG, et al. Endoscopic ultrasound fine-needle aspiration diagnosis of synchronous primary pancreatic adenocarcinoma and effects on staging and resectability. Clin Gastroenterol Hepatol. 2017; 15(2):299-302.e4.
doi: 10.1016/j.cgh.2016.08.009
|
)
